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Objectives: To evaluate and compare practices regarding the diagnosis, isolation
measures, and treatment of tuberculosis (TB) in high-income countries and mainly
in Europe.
Materials and Methods: A survey was conducted from November 2018 to April 2019
within the European Society of Clinical Microbiology and Infectious Diseases Study Group
for Mycobacterial Infections (ESGMYC). The practices observed were compared to the
main international guidelines.
Results: Among 136 ESGMYC members, 64 (17 countries) responded to the
questionnaire. In their practice, two (20.7%) or three sputum samples (79.3%) were
collected for the diagnosis of pulmonary TB, alternatively induced sputum (n = 37,
67.2%), bronchoscopy (34, 58.6%), and gastric aspirates (15, 25.9%). Nucleic acid
amplification tests (NAATs) were performed by 41 (64%) respondents whatever the smear
result and by 47 (73%) in case of smear-positive specimens. NAAT and adenosine
deaminase measurement were used for extrapulmonary TB diagnosis in 83.6 and 40.4%
of cases, respectively. For isolation duration, 21 respondents (42.9%) were keeping
isolation until smear negativity. An initial treatment without ethambutol was offered
by 14% (n = 9) of respondents. Corticosteroid therapy, cerebrospinal fluid opening
pressure testing, and repeated lumbar puncture were carried out for central nervous
system TB by 79.6, 51.9, and 46.3% of the respondents, respectively. For patients
with human immunodeficiency virus–TB coinfection, the preferred antiretroviral therapy
included dolutegravir 50mg twice a day (56.8%). Comparing with the recommendations
of the main guidelines, the practices are not totally consistent.
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Conclusion: This study shows heterogeneous practices, particularly for diagnosis,
and isolation, although rapid molecular testing is implemented in most centers. More
standardization might be needed.
Keywords: tuberculosis, survey, Europe, guidelines, harmonization, diagnosis, treatment
INTRODUCTION
In 2017, 10 million people were diagnosed with tuberculosis (TB)
in the world (1, 2). Although the European region accounted
for only 3% of all cases (3), TB remains a common infection.
Despite a rate of latent TB estimated at 23% of the world
population, there are very large disparities in incidence between
continents and countries with an incidence of fewer than 10
per 10,000 inhabitants in Western Europe to more than 500
per 100,000 for countries such as South Africa, the Philippines,
and Mozambique (2). The overall objective of the World Health
Organization (WHO) by 2035 (The End TB strategy) is to reduce
the number of deaths from TB by 95% (compared to 2015) and
to reduce the incidence rate of TB by 90% to fewer than 10 per
100,000 people. In 2016, 58,994 cases of TB were reported in 30
European Union/European Economic Area (EU/EEA) countries
(2). The decreasing notification rates observed in most countries
are reassuring, but annual rates of decline are still insufficient to
achieve the WHO target of TB elimination by 2050 in European
low-incidence countries. Multidrug-resistant (MDR) TB was
reported for 3.7% of 36,071 cases with drug susceptibility testing
results and continues to be the highest (more than 10%) in the
three Baltic countries. Extensively drug-resistant (XDR) TB was
reported for 20.1% of 984 MDR TB cases tested for second-line
drug susceptibility (4). Data on human immunodeficiency virus
(HIV) coinfection remained widely incomplete in Europe. Of all
TB cases with known HIV status, 4.5% were coinfected with the
virus (5).
An evaluation of TB case management in the EU/EEA
countries, with special focus on MDR and XDR-TB, was
conducted in 2010, using a standardized survey tool in five
European centers. Deviations from international standards of
TB care were observed in the following areas: surveillance (no
information available on patient outcomes); infection control
(lack of respiratory isolation rooms/procedures and negative-
pressure ventilation rooms); clinical management of TB, MDR-
TB, and HIV coinfection (inadequate bacteriological diagnosis,
regimen selection, and treatment duration); laboratory support;
and diagnostic/treatment algorithms (6).
A response to this need of harmonization has already
been initiated through the development of European Union
Standards for TB Care (ESTC) in 2012 with an update in 2017.
They identified key standards for the diagnosis, management,
prevention, and control of TB, MDR-TB, and XDR-TB. These
standards aim to support health care workers in optimizing
TB case management and thus at contributing to improved TB
control in the EU/EEA (7–11). In fact, after the implementation
of these standards, the knowledge of appropriate TB case
management in high-income countries and in particular the
TABLE 1 | Summary of the questionnaire.
Respondents Name, country, institution, age, profession
Medical information used for the practice
Microbiological TB
diagnosis
Investigations for a suspicion of active pulmonary
tuberculosis
Management of NAAT for pulmonary TB
Microbiological monitoring
Management of NAAT for non-pulmonary samples
Criteria for using ADA
TB meningitis: diagnosis and management of
corticosteroids and rifampicin
Criteria for using IGRA and TST
Isolation practices Kind of isolation room
Duration of isolation and circumstances to stop isolation
Isolation criteria of smear negative patients
Hospital discharge criteria
TB treatment Standard treatment of tuberculosis
Fluoroquinolones treatment criteria
Ethambutol if no isoniazid resistance mutation
B6 vitamin treatment criteria
Ophtalmology exam and ethambutol
Drug blood levels following TB treatment
HIV treatment in case of TB coinfection
Management of latent TB in HIV patients
Management of TB compliance
NAAT, Nucleic acid amplification tests.
different European countries is scarce. The main aim of this
study was therefore to verify the current good homogeneity
of practices of the different actors involved in the fight
against TB and to compare them with the main national or
international recommendations.
MATERIALS AND METHODS
A survey was conducted from November 2018 to April
2019 among members of the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) Study Group
for Mycobacterial Infections (ESGMYC), an offshoot of the
ESCMID. The questionnaire was initially sent out on November
8, 2018, with subsequent reminders, the last being sent on
March 15, 2019. The online questions comprised 63 items
and focused on three topics: (1) diagnosis of TB, (2) isolation
and prevention of TB transmission, and (3) TB treatment
(summarized in Table 1). Descriptive statistics were used to
































TABLE 2 | Microbiological TB diagnosis: synthesis of the international recommendations and main results from the ESGMYC survey.
Diagnostic
tools




• Three sputum specimens
• Sputum volume of at least 3ml
(optimal 5–10ml)
• Both liquid and solid culture (at
least one liquid culture on
all specimens)
• Three sputum specimens
• Preferably one early
morning sample
• Three sputum specimens
• Both liquid and solid culture
• At least two sputum
specimens (at least one early
morning) for microscopic
examination
• Samples can be collected on
the same day
• Good quality sputum
• At least liquid culture
• Phenotypic drug susceptibility
testing (DST)
• Sputum collection in the early
morning (97%)
• Three samples (81%)











• Three sputum inductions or
Three gastric lavages
• Induction of sputum or
bronchoscopy and lavage
in adults
NA • Sputum induction
• Bronchoscopy/bronchoalveolar
lavage
• Gastric lavage in children
• Induced sputum (66%)
• Bronchoscopy (59%)





• NAAT on the initial specimen
• A rapid molecular drug
susceptibility testing for
rifampicin with or without
isoniazid
• Genotyping in regional
laboratory for each
mycobacterial culture-positive
• NAAT on primary specimens if
clinical suspicion of TB
disease and/or
• HIV-positive patient, or
• Rapid information about
mycobacterial species would
alter the person’s care, or
• Need for a large contact
tracing initiative is
being explored.
• NAAT on at least
one specimen




• For DST, if use of WGS, results
must be confirmed by
phenotypic testing.
• Systematically done (64%)
• Detection of resistance
mutations to rifampicin (84%),
isoniazid (29%), and others
drugs (7%)
• Mutations sought for INH
resistance were katg gene and
InhA promoter (64%), or only
katG gene (15%)




• Cell counts and biochemistry
on fluid specimens
• ADA on fluid from pleural TB,
meningitis, peritoneal, or
pericardial TB
• Free IFN-γ on fluid from
suspected pleural or peritoneal
TB
• Smear microscopy for
suspected extrapulmonary TB
• NAAT from sites of
extrapulmonary TB
• Histological examination
• Addition of a spontaneously
produced respiratory sample
• Pleural TB: ADA, sputum
samples and pleural biopsy
• Meningeal TB: CSF fluid
analysis, ADA, and NAAT
• Lymph node: biopsy (+
histology), aspirate (+
cytology), NAAT
• Pericardial TB: biopsy of
pericardium (+histology),
pericardial fluid (+ cytology),
NAAT, ADA
• Disseminated TB: biopsy
(lung, liver, and bone marrow),
bone marrow aspirate,
bronchial lavage, appropriate
CSF tests, and blood culture
NA • Tests recommended for all
cases: microscopy, NAAT, and
culture, histopathology
• NAAT (85%)
• ADA (40%): on pleural fluid
(96%), CSF (40%), and
peritoneal fluid (24%)
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analyze the results of the survey. The data were analyzed
using STATA 10.0 (StataCorp LP, College Station, TX, USA).
Paris-Seine-Saint-Denis University Hospitals Committee review
waived the requirement for ethical approval for this study
because of absence of interventional research on the human
person, in accordance with the national legislation and the
institutional requirements.
In a second step, in order to understand the differences in the
management of TB in high-income countries, we compared the
participants’ responses to the main principles of TB management
according to the following international recommendations:
Infectious Disease Society of America/Centers for Disease
Control/American Thoracic Society (IDSA/CDC/ATS)
guidelines (12, 13), National Institute for Health and Care
Excellence (NICE) guidelines (14), ERS/ECDC (European
Respiratory Society/European Centers for Disease Control)
guidelines (11), WHO (15), and the recommendations of the
French Hospital Hygiene Society (16). These are summarized in
Tables 2–4 for comparing the proposals of each academic society.
RESULTS
Respondents
Among 136 ESGMYC members, 64 (47.1%) responded to the
questionnaire representing 14 European countries (Albania,
Croatia, Denmark, Germany, Greece, France, Italy, Netherlands,
Norway, Romania, Spain, Sweden, Switzerland, Turkey, and the
United Kingdom), with 1–13 per country, and 3 non-European
countries (New Zealand, Singapore, and Australia; Figure 1).
Median age was 44 years (interquartile range = 38–51 years).
The participants were working in an infectious diseases (67%,
n= 43/64) or clinical microbiology (30%, n= 19/64) department.
Sources of medical information for their practice were national
guidelines alone for 8% (n = 5/64) of them, international
guidelines only for 11% (n= 7/64), and an association of both for
64% (n = 41/64). TB specialist opinion was consulted, alone or
together with other sources, by 50% (n = 32/64) of respondents.
Among international recommendations, the main source was the
WHO guidelines for 34% of respondents (n= 15/44).
Microbiological TB Diagnosis
For the microbiological diagnosis of pulmonary TB, 97%
(n = 62/64) of respondents used to collect at least one
sputum in the early morning on an empty stomach, with
19% (n = 12/64) and 81% collecting two or three samples,
respectively. The two remaining responders collected induced or
spontaneous sputum at admission or randomly timed sputum
sample. Multiple samples are usually taken during 3 consecutive
days (58%, n = 37/64), or 2 (33%, n = 21/64) or within
the same day (17%, n = 11/64). If the patient could not
produce sputum, the alternatives were induced sputum (66%,
n = 42/64), bronchoscopy aspirate (59%, n = 38/64), and gastric
aspiration (27%, n= 17/64).
A rapid molecular test was performed systematically by
41/64 (64%) respondents, on one (31%, n = 14/45) or multiple
respiratory specimens (33%, n = 15/45). In case of strong
suspicion of pulmonary TB with negative sputum smears,
16/64 (25%) respondents would start treatment, 11/64 (17%)
would wait for the culture result before starting, and 44/64
(78.6%) would perform additional diagnostic tests, namely,
rapid molecular tests (66%), or bronchoscopy aspirate testing
(61.3%). In case of positive sputum smear, a rapid molecular
test was performed to detect mutations conferring resistance to
rifampicin by 84% (n = 52/64), to isoniazid by 29% (n = 18/62),
and to other drugs by 7% (n = 4/62), whereas 10 (16%) did not
perform any rapid molecular test. Regarding the type of mutation
sought for isoniazid resistance, among the 26 microbiologists
who gave an answer, 17 (65%) perform rapid molecular tests
to detect mutations in both katG gene and the inhA promoter,
and four only in the katG gene (15%). Eight respondents (31%)
were looking for genotypic resistance to other drugs besides
rifampicin and isoniazid, with five of them performing whole-
genome sequencing.
In the case of positive culture, of 61 respondents, 38 (62%)
were asking for molecular detection of rifampicin resistance
mutation, 24 (39%) for an isoniazid resistance mutation, and 9
(15%) for resistance mutations to other drugs, whereas 23 (38%)
were not looking for genotypic resistance.
For the diagnosis of extrapulmonary TB, nucleic acid
amplification test (NAAT), and measurement of adenosine
deaminase (ADA) were performed in 85% (n= 52/61 responses)
and 40% (n = 25/62 responses) of cases, respectively. ADA was
performed mainly for the diagnosis of pleural effusion (96%,
n = 24/25), but also on the cerebrospinal fluid (CSF) (40%,
n = 10/25) in case of suspicion of TB meningitis and on
peritoneal fluid (24%, n = 6/25). Sputum smear was repeated
after 2 and 6 months of treatment by 53/63 (83%) and 37/63
(58%) participants, respectively. Overall, interferon-γ release
assays (IGRAs) and tuberculin skin testing (TST) were performed
by 31% (n = 20/64) and 23% (n = 15/64) of respondents,
respectively, even for the diagnosis of active TB.
Isolation Practices
Overall, 23% (n = 15/63) of respondents used a conventional
single room to isolate pulmonary TB patients, whereas 77%
(n = 50/63) reported using a negative-pressure room whatever
the drug susceptibility profile of the strain. Regarding the
duration of isolation for pulmonary TB with smear-positive
sputum, 23/64 (36%) respondents adopted a standardized
duration of 2 to 3 weeks, whereas 23/64 (36%) reported waiting
for the sputum smear-negative conversion. In case of patients
hospitalized with a suspicion of pulmonary TB but negative
sputum smears and pending culture results, 18/64 (28%) of
the respondents did not isolate the patient. Patients with a
positive sputum smear were allowed to leave the hospital by 75%
(n = 48/64) of respondents, in the following cases: if they agreed
to wear a mask (n = 31/48, 65%), if there were no other people
at home (n = 39/48, 81%), and in the absence of children (n =
29/48, 60%) or of immunocompromised individuals (n = 36/48,
75%) at home.
TB Treatment
A majority of respondents (81%, n = 52/64) used the standard
first-line treatment with isoniazid, rifampicin, pyrazinamide,
































TABLE 3 | Isolation measures recommended for pulmonary tuberculosis patients in healthcare settings: synthesis of international recommendations and ESGMYC survey main results.
Isolation
measures





Up to 2 weeks if:
• No suspicion of resistance
• Decrease of cough intensity
• Low initial smear grade
• No immunocompromised
patients in the same ward
Isolation until:
• Patient under standard multi
drug anti TB therapy,
• Clinical improvement and
• Three consecutive
AFB-negative smear results of
sputum specimens
Up to 2 weeks if:
• (Complete) adherence to
treatment
• Resolution of cough
• Improvement on treatment
• Low initial smear grade (2 or
less)
• No cavitation















Isolation until culture results are
available




NA NA Single room/negative pressure




Negative pressure room (77%)






NA Non infectiousness if:
• Negligible likelihood of MDR
TB
• Anti TB therapy for 2–3 weeks
• Complete adherence to
treatment
• Clinical improvement
(reduction of cough, or of the
grade of the sputum AFB
smear result
• Close contacts identified
• No continuing clinical or public
health need for admission
• unlikely to be rifampicin
resistant
• To avoid congregate settlings
in the first 2 weeks
of treatment
NA To leave the hospital in case
of positive smear sputum (75%)
pending of conditions
• Mask (65%)
• No other people at home (81%)
• Absence of children at home
(60%) or
• No immunocompromised
people (75%) at home
MDR-TB, multidrug-resistant tuberculosis.

















































































TABLE 4 | Drug-susceptible tuberculosis treatment: synthesis of international recommendations and ESGMYC survey main results.
Treatment
scheme
IDSA/ATS/CDC 2017 (13) NICE 2016 (14) WHO 2010/2017 (15) ERS/ECDC 2017 (11) ESGMYC survey (% of respondents)
Intensive phase • INH/RIF/PZA/EMB
• Stop EMB if susceptibility to RIF
and INH
INH/RIF/PZA/EMB for 2 months INH/RIF/PZA/EMB for 2 months INH/RIF/PZA/EMB for 2 months • INH/RIF/PZA/EMB (81%)
• Tritherapy without ethambutol (14%)
Continuation
phase
INH/RIF INH/RIF for 4 months INH/RIF for 4 months INH/RIF for 4 months NA
Doses • Intensive phase: 7 days/week for 56
doses or 5 days/week for 40 doses*
• Continuation phase: 7 days/week for
126 doses or 5 days/week for
90 doses**
• Fixed-dose combination tablet
• Dosing regimens of fewer than
three times per week are not
recommended
• Daily dosing schedule
is recommended
• Fixed-dose combination tablet
• Daily dosing
schedule is recommended





To all persons at risk of neuropathy*** During all the treatment NA NA Systematically for 89% of respondents
HIV co-infection • 6 months treatment duration
• 9 months if no antiretroviral therapy
• Caution with drug–drug interactions
• 6 months duration
• Caution with
drug–drug interactions
• 6 months duration
• Start of antiretroviral treatment
within 8 weeks (within the first
2 weeks if CD4 counts
<50 cells/mm3 )
Delay between the initiation of
TB therapy and the start of
antiretroviral treatment of at least
14 days
• Associated antiretroviral therapy:
dolutegravir 50mg bid (60%), efavirenz
600mg daily (35%), a protease inhibitor
with rifabutin (17%), raltegravir 800mg
bid (15%), raltegravir 400mg bid (13%),
and efavirenz 800mg daily (6%).
• Preventive treatment for all HIV-positive
patients with latent TB infection (100%)
Adjunctive
corticosteroids
• TB pericarditis: not to be used routinely
(if large effusions, high levels of
inflammatory cells or markers, early
signs of constriction)
• Central nervous system TB:
dexamethasone or prednisolone for
6–8 weeks
• Central nervous system TB
and active pericardial TB:
dexamethasone (CNS) or
prednisolone (CNS, pericardial)
• TB meningitis: dexamethasone
or prednisone first 6–8 weeks
• TB pericarditis: initial adjuvant





during the first 6–8 weeks
of treatment
• TB pericarditis
• Renal TB: to prevent ureteric
stenosis
• Spinal TB: if spinal
cord compression
• Use of corticosteroids for
neuro-meningeal TB (80%)
• Duration of treatment with corticosteroids
from 2 (10%) to 12 weeks (5%)
Adjunctive
surgery
NA • Central nervous system TB
with raised intracranial
pressure
• Spinal TB with spinal instability





• INH/RIF/PZA/EMB for 2 months
then INH/RIF 7–10 months
• Repeated lumbar punctures
INH/RIF/PZA/EMB for 2 months
(with pyridoxine) then INH/RIF 10
months
(with pyridoxine)
NA NA • Measurement of CSF pressure (51%)
• Repeated lumbar punctures (46%)
Culture negative
tuberculosis
• Bronchoscopy with bronchoalveolar
lavage and biopsy
• Start treatment
• Duration 4 months if clinical or
radiographic response after 2 months of
intensive phase therapy
Start treatment without waiting




















































































TABLE 4 | Continued
Treatment
scheme
IDSA/ATS/CDC 2017 (13) NICE 2016 (14) WHO 2010/2017 (15) ERS/ECDC 2017 (11) ESGMYC survey (% of respondents)
Response to
therapy
NA NA Follow up smear microscopy at
time of completion of the
intensive phase and 5–6 months
if initial smear positive
Follow up smear microscopy and
culture at least at time of
completion of the intensive
phase
Sputum smear repeated after:
• 2 months (83%)
• 6 months (58%) of treatment
Optic neuritis Visual acuity and color discrimination tests
monthly during EMB use
NA NA NA Ophthalmology assessment during the first
2 months of ethambutol treatment (50%)
Therapeutic
Drug Monitoring
• Suspicion of drug malabsorption, drug
underdosing, and clinically important
drug-drug interactions
• Delayed sputum conversion or
treatment failure
• Reduced renal function
• Treatment for drug-resistant tuberculosis
NA NA Therapeutic drug monitoring if
poor response to treatment
(underdosing or malabsorption)




• Only in specific cases (23%)
Management of
IRIS
• Mild IRIS: TB and HIV treatment
continued, and anti-inflammatory drugs
• Severe IRIS: drainage for pleural
effusions or abscesses, corticosteroids
(2–4 weeks of treatment with
subsequent tapering over a period of
6–12 weeks or longer)
NA NA NA NA
Recurrence • Retreatment using the standard
intensive phase regimen
• Rapid molecular tests to
detect resistance
NA • Drug-susceptibility testing
before the start of treatment
• Rapid molecular tests
if possible
NA NA
Adherence Suggest using DOT NA • Health education and
counseling
(adherence interventions)
• DOT (or VOT:
Video observed Treatment)
NA Interpreter use (56%)
Nurse specialized in therapeutic education
(48%)
Systematic DOT (47%)
Hospitalization for the full duration of
treatment (28%)
DOT at home with a nurse (61%)
INH, isoniazid; RIF, rifampicin; PZA, pyrazinamide; EMB, ethambutol; TB, tuberculosis; CNS, central nervous system; IRIS, immune reconstitution inflammatory syndrome; DOT, directly-observed therapy.
*Preferred regimen.
**Extend the continuation phase for patients with cavitation on the initial chest radiography and patients who have culture positive after completion of 2 months of therapy.
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FIGURE 1 | Europe map presenting the number of respondents per country.
and ethambutol for 2 months, followed by 4 months of
treatment with isoniazid and rifampicin; but 14% (n = 9/64)
of respondents offered an initial treatment without ethambutol.
Fluoroquinolones were never prescribed as part of first-line
treatment by 29/61 (45%) of respondents; conversely, 5/61
(8%) and 26/61 (41%), respectively, used them under certain
conditions such as bone TB or suspicion of resistance to
isoniazid. Overall, 30% (n = 19/63) of respondents reported to
discontinue ethambutol treatment in the absence of mutations
conferring resistance to isoniazid. Among respondents, 89%
(n = 57/63) systematically gave B6 vitamin therapy. With regard
to treatment monitoring, 50% (n = 32/62) of respondents
performed an ophthalmology assessment during the first 2
months of ethambutol treatment. Overall, 50% (n = 32/64) of
respondents never performed therapeutic drug monitoring for
rifampicin and isoniazid, 17% (n= 11/64) routinely performed it,
and 23% (n= 15/64) performed it only in specific cases (i.e., HIV
infection, overweight, renal insufficiency). For neuromeningeal
TB cases, 80% (43/54) of respondents added corticosteroids to
the TB treatment for a variable duration, from 2 (10%, n = 4/40
respondents) to 12 weeks (5%, n = 2/40). The measurement of
CSF pressure and repeated lumbar punctures were performed
by 51% and 46% of the 59 respondents, respectively. In case of
HIV coinfection, the most frequently used antiretroviral drugs
were dolutegravir 50 mg twice a day (BID) (60%, n = 29/48
respondents), efavirenz 600mg daily (35%, n= 17/48), a protease
inhibitor with rifabutin (17%, n = 8/48), raltegravir 800 mg
BID (15%, n = 7/48), raltegravir 400 mg BID (13%, n = 6/48),
and efavirenz 800 mg daily (6%, n = 3/48). All respondents
offered preventive treatment to HIV-positive patients with latent
TB infection, using the following: isoniazid for 6 months (84%,
n = 43/51 respondents), isoniazid and rifampicin for 3 months
Frontiers in Public Health | www.frontiersin.org 8 September 2020 | Volume 8 | Article 443
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(24%, n = 12/51), rifampicin for 3–4 months (24%, n = 12/51),
or isoniazid plus rifapentine for 3 months (4%, n = 2/51). To
optimize adherence and treatment support, clinicians used an
interpreter (56%, n = 36/64), a nurse specialized in therapeutic
education (48%, n = 31/64), systematic Directly Observed
Therapy (DOT) (47%, n = 30/64), or hospitalization for the full
duration of treatment (28%, n = 18/64). As an alternative to
hospitalization, 39/64 (61%) offered a DOT at home with a nurse.
DISCUSSION
TB continues to be a priority public health challenge in high-
income countries. While EU/EEA countries adopted the key
principles of TB control and elimination through the Europe-
specific consensus-based documents born within the Wolfheze
initiative and subsequent documents, a uniform set of guidelines
summarizing essential standards to guide European clinicians
and health care workers was developed only in 2012 (7, 8). Both
International Standards for Tuberculosis Control (ISTC) and
ESTC prescribe a widely accepted level of TB care, to guide all
health care providers and clinicians, both public and private, in
achieving optimal standards in managing individuals who have
active TB, latent TB infection, or signs and symptoms compatible
with the disease. The standards are designed to complement
existing national or international guidelines and are consistent
with the WHO definitions and recommendations (15, 17).
Our survey of TB management shows that practical attitudes
currently can differ in some respects.
Regarding the diagnosis of TB, the practices are relatively
consensual with the continued use of sputum examination,
although the modalities may differ in number or timeframe (19).
It should be noted, however, that 13.8% of participants performed
only one sputum examination, whereas the guidelines always
recommend performing at least two sputum smears (Table 1).
Alternative examinations when patients were unable to provide
a sputum sample vary according to the centers with equally
heterogeneous guidelines: IDSA/ATS/CDC recommendations
favor sputum induction compared to bronchoscopy. NICE
guidelines are the only ones to propose gastric lavage, whereas
25.9% of respondents use it in clinical practice (Table 1) (20, 21).
We observed that almost all centers use NAAT, although these
tests are not yet carried out systematically for the diagnosis
of TB (only 62.1% of respondents) as recommended by the
guidelines (19, 22, 23). Despite recommendations to look for
mutations conferring resistance to rifampicin and isoniazid,
16% of participants did not perform rapid molecular detection
testing for rifampicin resistance in case of smear-positive patients
(24, 25). For extrapulmonary TB, a majority of participants
(86.3%) in the survey performed several rapid molecular tests
as recommended by international guidelines. In contrast, the
measurement of ADA was not universally used (40%), and it
was mainly confined to pleural fluid. This recommendation is
not consistent across all guidelines, because the ADA is used
only for the ATS/ IDSA/CDC and NICE guidelines for pleural
fluid, peritoneal fluid, and CSF. The monitoring of sputum
smear microscopy and sputum culture is only recommended
in the ERS/ECDC and WHO guidelines at least at the end
of completion of intensive phase and actually performed after
2 months of treatment by most participants (82.5%). Finally,
it should be noted that almost a third and a quarter of the
responders, respectively, used IGRA and TST tests for diagnosis,
whereas this is not recommended in most guidelines. These tests
cannot effectively differentiate active and latent TB, even though
a phlyctenular TST could predict rather an active TB (26).
Concerning the prevention of the risk of transmission of
TB, the ERS/ECDC and NICE guidelines clearly specify the
need to isolate the patient in a negative-pressure chamber,
whereas 22% of the participants did not (14, 18). The isolation
duration of contagious patients remains controversial, with 36%
of respondents having adopted standardized isolation duration of
2–3 weeks, like the guidelines of NICE and the French Hospital
Hygiene Society (14, 16); 43% prefer to wait for sputum smear
conversion, as recommended by WHO and ATS/IDSA/CDC
guidelines (13, 15). It should be noted that the conditions for
patients discharged from health care facilities remains poorly
studied, and this lack of evidence is reflected in the international
recommendations from academic societies.
Regarding the treatment of TB, the initial treatment with
four drugs is highly consensual between the respondents and
the different recommendations; however, 14% still prescribed
an initial treatment with only three drugs (respondents from
different countries). The role of rapid molecular tests for
resistance to isoniazid in guiding the withdrawal of ethambutol
from the intensive phase treatment is yet unclear. The role of
fluoroquinolones in first-line treatment, pyridoxine prophylaxis,
CSF pressure measurement, and therapeutic drug monitoring
should be better defined with additional studies. Similarly,
monthly ophthalmologic monitoring of ethambutol patients is
recommended only by the North American ATS/IDSA/CDC
guidelines (13). On the other hand, the use of corticosteroids in
the treatment of central nervous system TB is well established
in the literature and among the various guidelines, whereas
20% of the participants in our survey did not routinely
prescribe corticosteroids. Among HIV-positive patients, it is well
established that the duration of TB treatment should be identical
to that of HIV-negative patients. The importance of managing
drug–drug interactions is also well emphasized in the different
guidelines, although there is no clear recommendation on which
antiretrovirals should be used in combination with rifampicin.
Counseling is mostly developed inWHO guidelines, which target
low-resource countries. The collaboration of the interpreter and
the nurse in therapeutic education is still infrequent for the
stakeholders of our study: 57 and 50%, respectively, whereas most
European countries report increasing TB rates among newly
arrived migrants (27, 28).
Analysis of Differences in Practice
It is difficult to analyze the variability of practices observed
between the different respondents. There may be variability
between countries due to different local recommendations
but also a disparity of human or economic resources. The
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availability of medications, funding of TB programs, laboratory
practice, staff availability, and TB epidemiology can differ
between countries, but this phenomenon is probably lower in
high-resource European countries than on other continents.
Furthermore, in our survey, 7% of respondents used only
local recommendations for TB care management, whereas 78%
also relied on international recommendations, which should
also limit the variability between countries. It must also be
emphasized that interindividual variability within the same
country is possible. Although the respondents are among the TB
experts for each country, their management practice cannot be
fully representative of their respective countries. For instance,
the practice survey conducted in France in 2013 with specialists
in infectious diseases, pneumology, and internal medicine
showed that different doctors often had very different habits
concerning the treatment of TB or the isolation of active TB
(29). Finally, the heterogeneity of practices can also be partially
explained by the heterogeneity between the different national or
international recommendations, as we have seen above. This lack
of consistency across the different guidelines, as it is the case, for
example, with regard to isolation practices, can be confusing for
the clinician.
The ISTC defined the essential level of care for managing
patients who have or are presumed to have TB or are at
increased risk of developing the disease. In a high-resource
setting, such as the EU/EEA, higher standards of care can be
attained with regard to TB diagnosis, prevention, and treatment.
On this basis, the ESTC was published in 2012 as standards
specifically tailored to the European setting. Since the publication
of the ESTC, new scientific evidence has become available,
and therefore, the standards were reviewed and updated in
2017. Despite these new standards tailored to the EU setting,
the harmonization of practices needs to be further improved.
This is conditioned by a better standardization of national and
international recommendations, a wider communication with
people in charge of TB, and complementary studies to increase
the level of evidence on controversial aspects of TB care. If
we take the example of the joint ERS and ESCMID guidelines
on the management of infections due to nontuberculous
mycobacteria, which are being updated, collaboration between
the various European academic societies would probably
be beneficial.
Our study has several limitations. First, our sample is too
small to be representative. Second, the responders were selected
within the ESGMYC group, with mainly microbiologists and
infectious disease specialists. Therefore, this sample does not
include a lot of pulmonary physicians, although they are also very
involved in TB care. Third, as mentioned above, the management
practice of the responders could not be fully representative of
their respective countries. Nevertheless, we think that this survey
gives an interesting overview of different practices in Europe
and highlights a heterogeneity in the management of TB that
should be confirmed by a study with larger sample. In conclusion,
WHO’s international recommendations for TB management are
focused on countries with high incidence. Recommendations
that are more adapted to the European socioeconomic and
epidemiological context have also been developed under the
auspices of the ERS and the ECDC. This study shows that the
management of TB is probably still heterogeneous within high-
income countries, in particular for the prevention of transmission
and the treatment. Concerning microbiological diagnosis, the
practices seem to be better standardized, as rapid molecular
testing takes an important role across most European centers.
With the main objective of control and eventual elimination
of TB, it seems necessary to better harmonize and disseminate
the recommendations for the management of TB in Europe.
European scholarly societies, and in particular ESCMID, should
play a prominent role.
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